Effects of celiprolol, a cardioselective beta-blocker, on respiratory function in asthmatic patients
- PMID: 1348481
Effects of celiprolol, a cardioselective beta-blocker, on respiratory function in asthmatic patients
Abstract
The aim of this study was to compare the pulmonary effects of a single dose of celiprolol 400 mg, versus bisoprolol 20 mg and the combination of celiprolol 400 mg plus propranolol 40 mg versus placebo plus propranolol 40 mg. We conducted a double-blind randomized cross-over study in 10 stable asthmatic patients (mean age +/- SD 31 +/- 7 yrs) with forced expiratory volume in one second (FEV1): 2.5 +/- 0.7 l. A three-day washout period preceded each treatment period. Measurements of respiratory function were done before treatment and after 90, 120 and 180 min. There was a significant increase of FEV1 (+12%) and forced vital capacity (FVC) (+8%) after celiprolol (p less than 0.05) and a decrease of FEV1 (-9%) after propranolol. Concerning the combination, celiprolol inhibits the bronchoconstrictor effects of propranolol. We conclude that celiprolol has bronchosparing properties in asthmatic patients, and even improves some of the ventilatory parameters.
Similar articles
-
Bronchosparing properties of celiprolol, a new beta 1, alpha 2-blocker, in propranolol-sensitive asthmatic patients.J Cardiovasc Pharmacol. 1986;8 Suppl 4:S40-2. J Cardiovasc Pharmacol. 1986. PMID: 2427851 Clinical Trial.
-
The bronchosparing effect of celiprolol, a new beta 1- alpha 2-receptor antagonist on pulmonary function of propranolol-sensitive asthmatics.J Clin Pharmacol. 1985 Jul-Aug;25(5):354-9. doi: 10.1002/j.1552-4604.1985.tb02854.x. J Clin Pharmacol. 1985. PMID: 2863289 Clinical Trial.
-
Celiprolol, atenolol and propranolol: a comparison of pulmonary effects in asthmatic patients.J Cardiovasc Pharmacol. 1986;8 Suppl 4:S105-8. J Cardiovasc Pharmacol. 1986. PMID: 2427836 Clinical Trial.
-
Celiprolol: a new beta adrenoceptor antagonist with novel ancillary properties.J Cardiovasc Pharmacol. 1986;8 Suppl 4:S29-32. J Cardiovasc Pharmacol. 1986. PMID: 2427849 Review.
-
[Intrinsic sympathomimetic action and its special features as demonstrated by the beta-1-receptor blocker celiprolol].Wien Klin Wochenschr Suppl. 1985;162:1-21. Wien Klin Wochenschr Suppl. 1985. PMID: 2861698 Review. German.
Cited by
-
Cardioselective beta-blocker use in patients with reversible airway disease.Cochrane Database Syst Rev. 2001;2002(2):CD002992. doi: 10.1002/14651858.CD002992. Cochrane Database Syst Rev. 2001. Update in: Cochrane Database Syst Rev. 2002;(1):CD002992. doi: 10.1002/14651858.CD002992. PMID: 11406056 Free PMC article. Updated.
-
Adverse reactions with beta-adrenoceptor blocking drugs. An update.Drug Saf. 1993 Oct;9(4):272-9. doi: 10.2165/00002018-199309040-00005. Drug Saf. 1993. PMID: 7903148 Review.
-
Formulary considerations in selection of beta-blockers.Pharmacoeconomics. 1993 Aug;4(2):104-21. doi: 10.2165/00019053-199304020-00005. Pharmacoeconomics. 1993. PMID: 10150154 Review.
-
Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease.Drugs. 1991 Jun;41(6):941-69. doi: 10.2165/00003495-199141060-00009. Drugs. 1991. PMID: 1715268 Review.
-
Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris.Drugs Aging. 1995 Nov;7(5):394-411. doi: 10.2165/00002512-199507050-00006. Drugs Aging. 1995. PMID: 8573993 Review.